China committee eyes supply chain, biotech as Moolenaar takes helm

[Han Patriot]

So when they can't win, they just block and create protectionism.

 

[冖_冖]

https://www.bloomberg.com/news/articles/2026-06-08/pentagon-names-biotech-firm-wuxi-apptec-to-chinese-military-list

Pentagon Names Biotech Firm WuXi AppTec to Chinese Military List​

June 8, 2026 at 9:50 PM UTC

The Pentagon has named major pharmaceutical contractor WuXi AppTec Co. to a list of firms associated with the Chinese military, a move that could threaten its business and complicate research being done by American drugmakers.

WuXi AppTec, based in China, has performed various services for many of the world’s largest pharmaceutical companies, including drug discovery. As of 2024, WuXi was producing much of the active base ingredient used in Eli Lilly & Co.’s obesity drug Zepbound, Bloomberg has reported.

Pentagon adds tech giant Alibaba, electric car maker BYD to Chinese military list

The Pentagon has added several prominent Chinese businesses to its list of Chinese military companies

abcnews.com

Pentagon adds tech giant Alibaba, electric car maker BYD to Chinese military list​

Being on the list prevents the companies from getting U.S. defense contracts.
ByDIDI TANG Associated Press
June 8, 2026, 5:32 PM

WASHINGTON -- The Pentagon has added several prominent Chinese businesses, including the tech giant Alibaba, electric car maker BYD and search engine Baidu, to its list of Chinese military companies, preventing them from getting U.S. defense contracts.

The list, updated and published Monday by the Pentagon, now sanctions well-known, non-state-owned Chinese companies that are not traditionally considered to be in the defense or security sector.

 

[冖_冖]

Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact

Eli Lilly has expanded its relationship with Abbisko Th | Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple targets.

www.fiercebiotech.com

Eli Lilly reunites with China's Abbisko in $1.9B, multiple target R&D pact​

By Nick Paul Taylor Jun 24, 2026 7:47am

Eli Lilly has expanded its relationship with Abbisko Therapeutics, committing up to $1.9 billion to get the Chinese biotech to apply its drug discovery and early development capabilities to multiple targets.

Abbisko partnered with Lilly in 2022 to collaborate on a small molecule drug candidate. While Abbisko mainly focuses on cancer, the biotech describes (PDF) the P151 drug candidate co-owned with Lilly as a cardiometabolic program. The company’s in-house preclinical pipeline includes a GIPR obesity program and a STAT6 project focused on eczema and lung diseases, plus a slate of solid tumor candidates.

The expanded relationship broadens Lilly’s exposure to Abbisko’s capabilities, although details of what the companies will collaborate on are scarce. Abbisko will work on multiple targets chosen by Lilly. The partners have yet to disclose the targets or the therapeutic areas covered by the agreement.

Abbisko will perform discovery and early development work on programs against Lilly’s targets. Assigning those tasks to the Shanghai-based biotech positions Lilly to benefit from the fast pace of early development in China. Last month, Bristol Myers Squibb and Pfizer struck deals to funnel certain internal programs through the early development capabilities of Chinese partners.

Lilly is paying an undisclosed upfront fee to Abbisko. Beyond that, Abbisko is in line to receive up to $1.9 billion in development, regulatory and commercial milestones and tiered royalties on annual net sales.

The agreement continues the breakneck dealmaking pace set by Lilly, which has deep pockets because of the success of its GLP-1 drugs. In the past month, Lilly has struck deals to buy three vaccine developers for up to $3.8 billion and neuroscience startup 4E Therapeutics for an undisclosed amount, while inking licensing pacts with AlzeCure, Ascidian Therapeutics, Haisco Pharmaceutical and Hanmi Pharm.

Lilly is also in pole position to acquire capsid delivery, zinc finger and modular integrase platforms, plus a prion disease program. Sangamo is selling the assets as part of its bankruptcy process. Lilly is the stalking horse bidder for the assets.